Table 2.
Univariate and analysis of overall survival.
| Variables | Before propensity matching | After propensity matching | ||||
|---|---|---|---|---|---|---|
| Statistics | HR(95%CI) | P-value | Statistics | HR(95%CI) | P-value | |
| Age | ||||||
| <60 | 405 (53.4%) | 1 | 152 (50.3%) | 1 | ||
| ≥60 | 353 (46.6%) | 1.3 (1.1, 1.5) | 0.007 | 150 (49.7%) | 1.3 (0.9, 1.7) | 0.121 |
| Sex | ||||||
| female | 242 (31.9%) | 1 | 84 (27.8%) | 1 | ||
| male | 516 (68.1%) | 1.2 (1.0, 1.5) | 0.021 | 218 (72.2%) | 1.6 (1.1, 2.2) | 0.07 |
| Smoking history | ||||||
| Never | 369 (48.7%) | 1 | 139 (46.0%) | 1 | ||
| Ever | 378 (49.9%) | 1.4 (1.2, 1.7) | <0.001 | 157 (52.0%) | 1.7 (1.3, 2.3) | <0.001 |
| unknown | 11 (1.5%) | 4.0 (2.2, 7.3) | <0.001 | 6 (2.0%) | 4.4 (1.9, 10.2) | <0.001 |
| ECOG PS | ||||||
| <2 | 609 (80.3%) | 1 | 248 (82.1%) | 1 | ||
| ≥2 | 92 (12.1%) | 1.5 (1.1, 1.9) | 0.003 | 32 (10.6%) | 1.9 (1.2, 2.9) | 0.003 |
| unknown | 57 (7.5%) | 1.3 (1.0, 1.8) | 0.051 | 22 (7.3%) | 1.4 (0.9, 2.3) | 0.151 |
| BMI* | ||||||
| <18.5 | 111 (15.2%) | 1 | 55 (18.2%) | 1 | ||
| ≥18.5, <25 | 535 (73.1%) | 0.9 (0.7, 1.1) | 0.351 | 217 (71.9%) | 0.9 (0.6, 1.3) | 0.688 |
| ≥25 | 86 (11.7%) | 0.7 (0.5, 1.0) | 0.049 | 30 (9.9%) | 0.6 (0.4, 1.1) | 0.127 |
| Pathology | ||||||
| adenocarcinoma | 564 (74.4%) | 1 | 215 (71.2%) | 1 | ||
| squamous cell carcinoma | 167 (22.0%) | 1.4 (1.2, 1.8) | 0.001 | 74 (24.5%) | 1.6 (1.1, 2.2) | 0.006 |
| others | 27 (3.6%) |
1.2 (0.7, 1.8) | 0.512 | 13 (4.3%) |
1.4 (0.7, 2.7) | 0.311 |
| Differentiation | ||||||
| poor | 267 (35.2%) | 1 | 103 (34.1%) | 1 | ||
| moderate | 79 (10.4%) | 0.8 (0.6, 1.1) | 0.22 | 33 (10.9%) | 0.8 (0.5, 1.2) | 0.292 |
| high | 23 (3.0%) | 0.8 (0.5, 1.3) | 0.449 | 8 (2.6%) | 1.2 (0.6, 2.6) | 0.64 |
| unknown | 389 (51.3%) | 0.7 (0.6, 0.8) | <0.001 | 158 (52.3%) | 0.7 (0.5, 1.0) | 0.059 |
| ALK fusion | ||||||
| negative | 287 (37.9%) | 1 | 117 (38.7%) | 1 | ||
| positive | 30 (4.0%) | 0.7 (0.4, 1.2) | 0.154 | 16 (5.3%) | 0.5 (0.2, 1.3) | 0.155 |
| unknown | 441 (58.2%) | 1.2 (1.0, 1.5) | 0.046 | 169 (56.0%) | 1.4 (1.0, 1.9) | 0.026 |
| EGFR mutation | ||||||
| negative | 195 (25.7%) | 1 | 86 (28.5%) | 1 | ||
| positive | 132 (17.4%) | 0.6 (0.4, 0.8) | <0.001 | 54 (17.9%) | 0.7 (0.5, 1.2) | 0.219 |
| unknown | 431 (56.9%) | 1.2 (1.0, 1.5) | 0.093 | 162 (53.6%) | 1.3 (0.9, 1.8) | 0.127 |
| Sum of metastasis organs | ||||||
| <2 | 145 (19.1%) | 1 | 56 (18.5%) | 1 | ||
| ≥2 | 599 (79.0%) | 1.4 (1.1, 1.7) | 0.008 | 241 (79.8%) | 1.4 (1.0, 2.1) | 0.071 |
| unknown | 14 (1.8%) | 1.3 (0.7, 2.4) | 0.348 | 5 (1.7%) | 1.9 (0.7, 5.3) | 0.234 |
| Treat type of 1st line therapy | ||||||
| Chemo | 378 (49.9%) | 1 | 194 (64.2%) | 1 | ||
| TKI | 118 (15.6%) | 1.0 (0.7, 1.2) | 0.754 | 54 (17.9%) | 1.0 (0.7, 1.4) | 0.916 |
| others | 262 (34.6%) | 1.4 (1.1, 1.7) | 0.001 | 54 (17.9%) | 1.0 (0.6, 1.5) | 0.911 |
| Sum of treatment line* | ||||||
| ≤3 | 521 (88.3%) | 1 | 263 (87.1%) | 1 | ||
| >3 | 69 (11.7%) | 0.5 (0.4, 0.7) | <0.001 | 39 (12.9%) | 0.4 (0.3, 0.6) | <0.001 |
| Hb | ||||||
| No anemia | 548 (72.3%) | 1 | 151 (50.0%) | 1 | ||
| Anemia | 210 (27.7%) | 1.3 (1.1, 1.6) | 0.008 | 151 (50.0%) | 1.7 (1.3, 2.3) | <0.001 |
ECOG PS: eastern cooperative group performance status, BMI: Body mass index, EGFR: epidermal growth factor receptor, ALK: Anaplastic Lymphoma Kinase, Treatment type of first-line therapy: Chemotherapy, Targeted therapy, others).
BMI* and Sum of treatment lines* had missing data
*p values<0.05 were considered statistically significant.